Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2	-	0.3	3.94	2.3
Revenue Growth (YoY)	-	-	-92.47%	71.69%	-49.06%
Cost of Revenue	-	-	5.58	37.64	56.41
Gross Profit	2	-	-5.28	-33.69	-54.12
Selling, General & Admin	5.34	8.33	13.26	20.62	28.82
Research & Development	0.29	1.32	-	-	-
Operating Expenses	5.63	9.65	13.26	20.62	28.82
Operating Income	-3.63	-9.65	-18.54	-54.31	-82.93
Interest Expense	-	-	-	-0.02	-
Interest & Investment Income	0.21	0.36	0.29	-	0.3
Other Non Operating Income (Expenses)	0.36	-	-	-	0.29
EBT Excluding Unusual Items	-3.06	-9.29	-18.25	-54.33	-82.35
Asset Writedown	-	-3.3	-	-	-
Other Unusual Items	-	-	-	2.68	4.54
Pretax Income	-3.06	-12.59	-18.25	-51.65	-77.8
Earnings From Continuing Operations	-3.06	-12.59	-18.25	-51.65	-77.8
Earnings From Discontinued Operations	-	7.33	-25.83	-	-
Net Income	-3.06	-5.26	-44.08	-51.65	-77.8
Net Income to Common	-3.06	-5.26	-44.08	-51.65	-77.8
Shares Outstanding (Basic)	3	2	2	2	2
Shares Outstanding (Diluted)	3	2	2	2	2
Shares Change (YoY)	7.70%	7.59%	11.03%	28.75%	11.04%
EPS (Basic)	-1.21	-2.25	-20.28	-26.39	-51.18
EPS (Diluted)	-1.21	-2.25	-20.28	-26.39	-51.18
Free Cash Flow	-4.33	-21.25	-40.61	-36.52	-74.01
Free Cash Flow Per Share	-1.72	-9.09	-18.69	-18.66	-48.69
Gross Margin	100.00%	-	-	-	-
Operating Margin	-181.40%	-	-6242.42%	-1377.83%	-3612.11%
Profit Margin	-152.85%	-	-14841.08%	-1310.17%	-3388.59%
Free Cash Flow Margin	-216.65%	-	-13673.74%	-926.53%	-3223.61%
EBITDA	-	-9.58	-18.48	-53.84	-80.64
D&A For EBITDA	-	0.07	0.07	0.47	2.3
EBIT	-3.63	-9.65	-18.54	-54.31	-82.93
EBIT Margin	-181.40%	-	-	-	-
Revenue as Reported	2	-	0.3	3.94	2.3

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q